Breast cancer (BRCA) and pancreatic adenocarcinoma (PAAD) are two significant malignancies that pose substantial challenges to global health. However, their early detections remain hindered by a lack of genetic markers. Our study aims to find prospective biomarkers that could serve as prognostic indicators for efficient drug candidates for BRCA and PAAD treatment. Our study found that top 10 hub genes (CDK1, BUB1, CCNB1, TPX2, etc.) were highly overexpressed in these cancers. And among them CDK1was the most significant, showing strong correlation with cancer progression and poor survival. While CDK1, a key cell cycle regulatory gene's role in cancer is well-known, we aimed to identify a phytochemical that interacts with it to regulate its dysregulation. Using bioinformatics tools, we analyzed gene expression data, highlightingCDK1as a key biomarker gene shared by both BRCA and PAAD. Our goal was to explore how a specific phytochemical could target CDK1, potentially offering a new treatment for these cancers.
Ferdoush et al. (Tue,) studied this question.